Drug intelligence / Profile preview

KH-1814

Development stage: Preclinical
Lead developer: KWHC
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

KH-1814 is an exosome-based therapy being developed by KWHC (KweHealth) for the treatment of neurodegenerative diseases, with a primary focus on Parkinson's disease. The therapy utilizes exosomes derived from specialized cells of perinatal tissues. These exosomes are designed to cross the blood-brain barrier and deliver therapeutic cargo, including trophic and repair factors, to modulate neurodegenerative processes. The goal of KH-1814 is to alleviate symptoms and potentially reverse disease-induced damage by promoting neural repair. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on KH-1814.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH-1814.

Explore the full profile